150 related articles for article (PubMed ID: 34302061)
41. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis.
Moriishi K; Mochizuki R; Moriya K; Miyamoto H; Mori Y; Abe T; Murata S; Tanaka K; Miyamura T; Suzuki T; Koike K; Matsuura Y
Proc Natl Acad Sci U S A; 2007 Jan; 104(5):1661-6. PubMed ID: 17234812
[TBL] [Abstract][Full Text] [Related]
42. Liver X receptors regulate natural killer T cell population and antitumor activity in the liver of mice.
Endo-Umeda K; Nakashima H; Uno S; Toyoshima S; Umeda N; Komine-Aizawa S; Seki S; Makishima M
Sci Rep; 2021 Nov; 11(1):22595. PubMed ID: 34799646
[TBL] [Abstract][Full Text] [Related]
43. Palmitate-induced activation of mitochondrial metabolism promotes oxidative stress and apoptosis in H4IIEC3 rat hepatocytes.
Egnatchik RA; Leamy AK; Noguchi Y; Shiota M; Young JD
Metabolism; 2014 Feb; 63(2):283-95. PubMed ID: 24286856
[TBL] [Abstract][Full Text] [Related]
44. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
Hwahng SH; Ki SH; Bae EJ; Kim HE; Kim SG
Hepatology; 2009 Jun; 49(6):1913-25. PubMed ID: 19378344
[TBL] [Abstract][Full Text] [Related]
45. Alpha-linolenic acid increases cholesterol efflux in macrophage-derived foam cells by decreasing stearoyl CoA desaturase 1 expression: evidence for a farnesoid-X-receptor mechanism of action.
Zhang J; Kris-Etherton PM; Thompson JT; Hannon DB; Gillies PJ; Heuvel JP
J Nutr Biochem; 2012 Apr; 23(4):400-9. PubMed ID: 21658928
[TBL] [Abstract][Full Text] [Related]
46. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
Kay HY; Kim WD; Hwang SJ; Choi HS; Gilroy RK; Wan YJ; Kim SG
Antioxid Redox Signal; 2011 Oct; 15(8):2135-46. PubMed ID: 21504366
[TBL] [Abstract][Full Text] [Related]
47. LXRα Promotes Hepatosteatosis in Part Through Activation of MicroRNA-378 Transcription and Inhibition of Ppargc1β Expression.
Zhang T; Duan J; Zhang L; Li Z; Steer CJ; Yan G; Song G
Hepatology; 2019 Apr; 69(4):1488-1503. PubMed ID: 30281809
[TBL] [Abstract][Full Text] [Related]
48. Differential Role of Liver X Receptor (LXR)
Hansmann E; Mennillo E; Yoda E; Verreault M; Barbier O; Chen S; Tukey RH
Drug Metab Dispos; 2020 Apr; 48(4):255-263. PubMed ID: 31980500
[TBL] [Abstract][Full Text] [Related]
49. Liver X receptor α induces 17β-hydroxysteroid dehydrogenase-13 expression through SREBP-1c.
Su W; Peng J; Li S; Dai YB; Wang CJ; Xu H; Gao M; Ruan XZ; Gustafsson JÅ; Guan YF; Zhang XY
Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E357-E367. PubMed ID: 28270440
[TBL] [Abstract][Full Text] [Related]
50. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
51. Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule.
Zhang Y; Zhang X; Chen L; Wu J; Su D; Lu WJ; Hwang MT; Yang G; Li S; Wei M; Davis L; Breyer MD; Guan Y
Am J Physiol Renal Physiol; 2006 May; 290(5):F1065-73. PubMed ID: 16368743
[TBL] [Abstract][Full Text] [Related]
52. Soy protein isoflavones differentially regulate liver X receptor isoforms to modulate lipid metabolism and cholesterol transport in the liver and intestine in mice.
González-Granillo M; Steffensen KR; Granados O; Torres N; Korach-André M; Ortíz V; Aguilar-Salinas C; Jakobsson T; Díaz-Villaseñor A; Loza-Valdes A; Hernandez-Pando R; Gustafsson JÅ; Tovar AR
Diabetologia; 2012 Sep; 55(9):2469-78. PubMed ID: 22739758
[TBL] [Abstract][Full Text] [Related]
53. TO901317 inhibits the development of hepatocellular carcinoma by LXRα/Glut1 decreasing glycometabolism.
Xiong T; Li Z; Huang X; Lu K; Xie W; Zhou Z; Tu J
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G598-G607. PubMed ID: 30817182
[TBL] [Abstract][Full Text] [Related]
54. SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity.
Lee DH; Park JS; Lee YS; Han J; Lee DK; Kwon SW; Han DH; Lee YH; Bae SH
Autophagy; 2020 Nov; 16(11):1949-1973. PubMed ID: 31913745
[TBL] [Abstract][Full Text] [Related]
55. The C57BL/6J Niemann-Pick C1 mouse model with decreased gene dosage has impaired glucose tolerance independent of body weight.
Jelinek D; Castillo JJ; Garver WS
Gene; 2013 Sep; 527(1):65-70. PubMed ID: 23769925
[TBL] [Abstract][Full Text] [Related]
56. The Hexane Fraction of cyperus rotundus Prevents Non-Alcoholic Fatty Liver Disease Through the Inhibition of Liver X Receptor α-Mediated Activation of Sterol Regulatory Element Binding Protein-1c.
Oh GS; Yoon J; Lee GG; Kwak JH; Kim SW
Am J Chin Med; 2015; 43(3):477-94. PubMed ID: 25967664
[TBL] [Abstract][Full Text] [Related]
57. Regulation of type 1 iodothyronine deiodinase by LXRα.
Sakane Y; Kanamoto N; Yamauchi I; Tagami T; Morita Y; Miura M; Sone M; Yasoda A; Kimura T; Nakao K; Inagaki N
PLoS One; 2017; 12(6):e0179213. PubMed ID: 28617824
[TBL] [Abstract][Full Text] [Related]
58. Pravastatin activates the expression of farnesoid X receptor and liver X receptor alpha in Hep3B cells.
Byun HW; Hong EM; Park SH; Koh DH; Choi MH; Jang HJ; Kae SH; Lee J
Hepatobiliary Pancreat Dis Int; 2014 Feb; 13(1):65-73. PubMed ID: 24463082
[TBL] [Abstract][Full Text] [Related]
59. Endogenous Liver Protections Against Lipotoxicity and Oxidative Stress to Avoid the Progression of Non-alcoholic Fatty Liver to more Serious Disease.
Barrios-Maya MA; Ruiz-Ramírez A; El-Hafidi M
Curr Mol Med; 2022; 22(5):401-420. PubMed ID: 34931979
[TBL] [Abstract][Full Text] [Related]
60. Quantitative proteomic profiling reveals hepatic lipogenesis and liver X receptor activation in the PANDER transgenic model.
Athanason MG; Ratliff WA; Chaput D; MarElia CB; Kuehl MN; Stevens SM; Burkhardt BR
Mol Cell Endocrinol; 2016 Nov; 436():41-9. PubMed ID: 27394190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
